Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-03-20
2010-11-09
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07829531
ABSTRACT:
Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
REFERENCES:
patent: 3445518 (1969-05-01), Shavel, Jr. et al.
patent: 4414205 (1983-11-01), Pettit
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4764368 (1988-08-01), Blatter et al.
patent: 4816444 (1989-03-01), Pettit et al.
patent: 4879278 (1989-11-01), Pettit et al.
patent: 4943628 (1990-07-01), Rosen et al.
patent: 4978744 (1990-12-01), Pettit et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5410024 (1995-04-01), Pettit et al.
patent: 5521284 (1996-05-01), Pettit et al.
patent: 5530097 (1996-06-01), Pettit et al.
patent: 5554725 (1996-09-01), Pettit
patent: 5585089 (1996-12-01), Queen et al.
patent: 5599902 (1997-02-01), Pettit et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5635483 (1997-06-01), Pettit et al.
patent: 5654399 (1997-08-01), Sakakibara et al.
patent: 5663149 (1997-09-01), Pettit et al.
patent: 5665860 (1997-09-01), Pettit et al.
patent: 5708146 (1998-01-01), Willner et al.
patent: 5714586 (1998-02-01), Kunstmann et al.
patent: 5741892 (1998-04-01), Barlozzari et al.
patent: 5767236 (1998-06-01), Kim et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5780588 (1998-07-01), Pettit et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840699 (1998-11-01), Sakakibara et al.
patent: 5965537 (1999-10-01), Ritter et al.
patent: 6004934 (1999-12-01), Sakakibara et al.
patent: 6033876 (2000-03-01), Lemke et al.
patent: 6034065 (2000-03-01), Pettit et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring et al.
patent: 6124431 (2000-09-01), Sakakibara et al.
patent: 6143721 (2000-11-01), Janssen et al.
patent: 6162930 (2000-12-01), Pinney et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6239104 (2001-05-01), Pettit et al.
patent: 6323315 (2001-11-01), Pettit et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6569834 (2003-05-01), Pettit et al.
patent: 6620911 (2003-09-01), Pettit et al.
patent: 6639055 (2003-10-01), Carter et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 6913748 (2005-07-01), Widdison
patent: 7090843 (2006-08-01), Francisco et al.
patent: 7091186 (2006-08-01), Senter et al.
patent: 7097840 (2006-08-01), Erickson et al.
patent: 7098305 (2006-08-01), Deghenghi et al.
patent: 7098308 (2006-08-01), Senter et al.
patent: 7276372 (2007-10-01), Law et al.
patent: 7425541 (2008-09-01), Dubois et al.
patent: 7498298 (2009-03-01), Doronina et al.
patent: 7553816 (2009-06-01), Senter et al.
patent: 7659241 (2010-02-01), Senter et al.
patent: 7662387 (2010-02-01), Law et al.
patent: 7674883 (2010-03-01), Bhaskar et al.
patent: 2001/0018422 (2001-08-01), Ritter et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0096392 (2004-05-01), Bhaskar et al.
patent: 2004/0141983 (2004-07-01), Law et al.
patent: 2004/0197325 (2004-10-01), Law et al.
patent: 2004/0235068 (2004-11-01), Levinson
patent: 2005/0014687 (2005-01-01), Anderson et al.
patent: 2005/0084449 (2005-04-01), Landes et al.
patent: 2005/0106644 (2005-05-01), Cairns et al.
patent: 2005/0107595 (2005-05-01), Cairns et al.
patent: 2005/0123536 (2005-06-01), Law et al.
patent: 2005/0180972 (2005-08-01), Wahl et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2005/0238650 (2005-10-01), Crowley et al.
patent: 2005/0256030 (2005-11-01), Feng
patent: 2005/0260212 (2005-11-01), Zhang et al.
patent: 2005/0272665 (2005-12-01), Schmid et al.
patent: 2006/0073152 (2006-04-01), Dennis
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0128970 (2006-06-01), Bliss et al.
patent: 2006/0233794 (2006-10-01), Law et al.
patent: 2007/0092940 (2007-04-01), Eigenbrot et al.
patent: 2007/0098715 (2007-05-01), Ettenberg et al.
patent: 2007/0160617 (2007-07-01), Ma et al.
patent: 2007/0258987 (2007-11-01), Francisco et al.
patent: 2008/0226657 (2008-09-01), Doronina et al.
patent: 2008/0248051 (2008-10-01), Doronina et al.
patent: 2008/0248053 (2008-10-01), Doronina et al.
patent: 2009/0041791 (2009-02-01), Feng
patent: 2009/0304721 (2009-12-01), Kinch et al.
patent: 199478159 (1995-04-01), None
patent: 2114156 (1994-07-01), None
patent: 0 598 129 (1994-05-01), None
patent: 0 659 759 (1996-02-01), None
patent: 0 695 757 (1996-02-01), None
patent: 0 695 758 (1996-02-01), None
patent: 0 695 759 (1996-02-01), None
patent: 06-234790 (1994-08-01), None
patent: 8-59693 (1996-03-01), None
patent: 09-077791 (1997-03-01), None
patent: 9-502993 (1997-03-01), None
patent: 2002-513402 (2002-05-01), None
patent: 2002-520335 (2002-07-01), None
patent: WO 93/03054 (1993-02-01), None
patent: WO 95/09864 (1995-04-01), None
patent: WO 96/14856 (1996-05-01), None
patent: WO 96/22384 (1996-07-01), None
patent: WO 96/33212 (1996-10-01), None
patent: WO 98/36765 (1998-08-01), None
patent: WO 99/35164 (1999-07-01), None
patent: WO 00/02906 (2000-01-01), None
patent: WO 00/47228 (2000-08-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/18032 (2001-03-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 02/43661 (2002-06-01), None
patent: WO 02/43661 (2002-06-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/008378 (2003-01-01), None
patent: WO 03/034903 (2003-05-01), None
patent: WO 03/043583 (2003-05-01), None
patent: WO 03074551 (2003-09-01), None
patent: WO 2004/010957 (2004-02-01), None
patent: WO 2004/032828 (2004-04-01), None
patent: WO 2005/084390 (2005-09-01), None
patent: WO 2006/071441 (2006-07-01), None
patent: WO 2006/083936 (2006-08-01), None
patent: WO 2007/030642 (2007-03-01), None
patent: WO 2007/059082 (2007-05-01), None
patent: WO 2007/062138 (2007-05-01), None
patent: WO 2007/070538 (2007-06-01), None
patent: WO 2007/109567 (2007-09-01), None
In The United States Patent and Trademark Office: Non-Final Rejection Office Action Summary of U.S. Appl. No. 12/016,978, Dated Apr. 14, 2010, 21 pages.
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer,”Molecular Cancer Therapeutics, 2004, 921-932.
Aherne et al., “Antitumour evaluation of dolastatins 10 and 15 and their measurements in plasma by radioimmunoassay,”Cancer Chemother. Phamiacol., 1996, 38, 225-323.
Alley et al., “Controlling the location of drug attachment in antibody-drug conjugates,”Proceedings of the AACR, 2004, 45, Abstract #627.
Bhaskar et al., “E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer,”Cancer Research, 2003, 63, 6387-6394.
Bowman et al. 1950, “N-substituted amino-acids. Part I. A new method of preparation of dimethylamino-acids,”. J. Chem. Soc.:1342-1351.
Carter., “Improving the Efficacy of Antibody-Based Cancer Therapies,”Nature Reviews, 1989, 1, 118-129.
Carter, P.J. et al., “Antibody-Drug Conjugates for Cancer Therapy,”The Cancer Journal, May/Jun. 2008, vol. 14, No. 3, pp. 154-169.
Dillman., “Monoclonal Antibodies for Treating Cancer,”Annals of Internal Medicine, 1989, 11.1, 592-603.
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 2003, 21(7), 778-784.
Doronina et al., “Errata and Corrigenda,”Nature Biotechnology, 2003, 21(8), 941.
Doronina et al., “Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to ta
Doronina Svetlana O.
Senter Peter D.
Toki Brian E.
Bradley Christina
Seattle Genetics Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Drug conjugates and their use for treating cancer, an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug conjugates and their use for treating cancer, an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug conjugates and their use for treating cancer, an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207846